| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Molecular definition of breast tumor heterogeneity.
|
Cancer Cell
|
2007
|
12.67
|
|
2
|
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
|
J Clin Oncol
|
2010
|
5.50
|
|
3
|
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.
|
J Allergy Clin Immunol
|
2003
|
5.43
|
|
4
|
Network modeling links breast cancer susceptibility and centrosome dysfunction.
|
Nat Genet
|
2007
|
4.69
|
|
5
|
Regulation of in situ to invasive breast carcinoma transition.
|
Cancer Cell
|
2008
|
4.46
|
|
6
|
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.
|
Sci Transl Med
|
2011
|
3.08
|
|
7
|
Cell type-specific DNA methylation patterns in the human breast.
|
Proc Natl Acad Sci U S A
|
2008
|
2.99
|
|
8
|
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
|
J Virol
|
2004
|
2.63
|
|
9
|
Do patients participating in clinical trials want to know study results?
|
J Natl Cancer Inst
|
2003
|
2.33
|
|
10
|
Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques.
|
J Virol
|
2005
|
2.01
|
|
11
|
Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses.
|
Proc Natl Acad Sci U S A
|
2004
|
1.55
|
|
12
|
Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus.
|
J Virol
|
2003
|
1.53
|
|
13
|
Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys.
|
PLoS Genet
|
2010
|
1.28
|
|
14
|
Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys.
|
J Virol
|
2005
|
1.24
|
|
15
|
Use of CD45 gating in three and four-color flow cytometric immunophenotyping: guideline from the National Institute of Allergy and Infectious Diseases, Division of AIDS.
|
Cytometry
|
2002
|
1.24
|
|
16
|
BRCA1/2 genetic testing in the community setting.
|
J Clin Oncol
|
2002
|
1.17
|
|
17
|
Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial.
|
J Clin Oncol
|
2005
|
1.17
|
|
18
|
Potent simian immunodeficiency virus-specific cellular immune responses in the breast milk of simian immunodeficiency virus-infected, lactating rhesus monkeys.
|
J Immunol
|
2008
|
1.09
|
|
19
|
Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods.
|
J Clin Microbiol
|
2012
|
1.03
|
|
20
|
Characteristics of lymphocyte subsets in HIV-infected, long-term nonprogressor, and healthy Asian children through 12 years of age.
|
J Allergy Clin Immunol
|
2010
|
1.00
|
|
21
|
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2.
|
AIDS Res Hum Retroviruses
|
2002
|
0.98
|
|
22
|
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
|
Breast Cancer Res Treat
|
2013
|
0.93
|
|
23
|
Germinal center function in the spleen during simian HIV infection in rhesus monkeys.
|
J Immunol
|
2006
|
0.91
|
|
24
|
Association of activating KIR copy number variation of NK cells with containment of SIV replication in rhesus monkeys.
|
PLoS Pathog
|
2011
|
0.91
|
|
25
|
Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer.
|
Cancer
|
2010
|
0.89
|
|
26
|
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
|
Breast Cancer Res Treat
|
2013
|
0.84
|
|
27
|
A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
|
Cancer
|
2004
|
0.81
|